Navigation Links
Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
Date:9/15/2010

Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and... -- MINNEAPOLIS, Minnesota, September 15, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries, FDA Approval Click to view news release full screen  

Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture

 

MINNEAPOLIS, Minnesota, September 15, 2010 /PRNewswire/ -- Angioslide, Inc. of Minneapolis, MN and Angioslide, Ltd. Herzliya, Israel, announced today that the company has commercialized the Proteus device for Embolic Capture Angioplasty (ECA) in the United States. The device combines an angioplasty balloon and embolic capture feature into one device, thus providing physicians with a simple and cost-effective method of capturing of embolic particles during angioplasty procedures. Proteus is a one of its kind device to combine balloon angioplasty and embolic capture to receive FDA clearance, which was received in April 2010. The Proteus device is presently indicated for use in the lower limbs during Percutaneous Transluminal Angioplasty (PTA) procedures.

Proteus joins the new class of medical devices aimed at treating peripheral arterial disease (PAD), one of the fastest-growing segments in the worldwide interventional marketplace. An estimated 10 million patients suffer from PAD in the U.S. alone, of whom approximately 1,000,000 undergo a revascularization or amputation procedure each year. PTA procedures are a common treatment for peripheral artery disease for opening up the artery to improve blood flow. However, one potential complication of a PTA procedure is debris from the artery wall being disturbed during the procedure and floating through the blood stream. In the worst case this floating debris can totally occlude the artery and cause complete lack of circulation to the lower limb.

The Proteus device combines a standard angioplasty balloon with a feature that can capture the debris that maybe liberated during the PTA procedure. Proteus has the same characteristics as a standard angioplasty balloon but the embolic capture feature allows debris to be trapped within the balloon and removed as the physician removes the angioplasty balloon at the end of the PTA procedure.

"We believe that Proteus and Embolic Capture Angioplasty (ECA) represents a major advancement in the approach to angioplasty procedures. We are actively commercializing the Proteus in the U.S. via our direct sales force. In a relatively short time we are already active in over 15 hospitals in US and are very pleased with the acceptance of the device," said Doron Besser, President and CEO of Angioslide

Besser added, "This entry of Proteus into the U.S. market for is expected to be only the first in a series of applications of the technology such as the coronary, renal and carotid vascular beds.

"I am very pleased with the use of the Proteus device in my patients. It is simple to use and cost effective and I can now be assured that my patients will have a significant reduction in risk from the PTA procedure," said Dr. Subhash Banerjee, Chief, Division of Cardiology, from VA North Texas Health Care System, Dallas, TX.

"Being part of the company's Scientific Advisory Board from its early days, I am very excited that Proteus has received FDA clearance for use in the lower limbs. Proteus and Embolic Capture Angioplasty will reduce the risk of complications for our patients and in the future could become the gold standard for angioplasty procedures," said Dr. John Laird, Medical Director, UC Davis Vascular Center, Sacramento, CA.

Investors in Angioslide include Ofer Hi-Tech, Viola Group, Itochu Corporation and Agate Medical Investments.

United States operations are led by Tom Doorley, Senior VP of Sales, and John Schorgl, both former executives with Schneider/Pfizer.

About Angioslide

Angioslide is a privately held company with headquarters in Herzliya, Israel. Its U.S. distribution headquarters is located in Minneapolis, MN. Its European distribution headquarters is located in Karlsruhe, Germany.

The Proteus product line, Embolic Capture Angioplasty and ECA are trademarks of Angioslide Ltd.

Note: This press release contains forward-looking statements that are based upon management's present expectations and are essentially uncertain. Actual results and timing of events could differ materially from current expectations and from any forward-looking statements.

The company's first product is Proteus which is indicated for use in the United States for usage in the lower limbs. Angioslide can be contacted at +972-9-970-3700 or info@angioslide.com


'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... --  Bernstein Liebhard LLP today announced that a securities ... Court for the District of Arizona ... persons or entities who purchased common shares of Insys Therapeutics ... March 3, 2015 through January 25, 2016 (the "Class Period").  ... violations of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 4, 2016  Montoya Love is recognized by Continental ... of Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager ... Manufacturing and selling a broad ... provides healthcare institutions, clinical laboratories and life science ... across the globe. ...
(Date:2/4/2016)... , Feb. 4, 2016 Frontier Pharma: ... Commercializing First-in-Class Innovation Chronic Obstructive ... with chronic inflammation of the airways and lungs. ... symptoms make the disease one of the leading ... death in the world. COPD is linked to ...
Breaking Medicine Technology:
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... , ... With the FCPX LUT: Summer pack from Pixel Film ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. ... By manipulating each pixel, LUT's can change each color range differently, it gives the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, hosted ... feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on Friday, ... on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - people ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy ... Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. ... dystrophy, ALS and related diseases that severely limit strength and mobility. , ...
Breaking Medicine News(10 mins):